Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
- Trevor J. Orchard1⇑,
- Wanjie Sun2,
- Patricia A. Cleary2,
- Saul M. Genuth3,
- John M. Lachin2,
- Paula McGee2,
- Andrew D. Paterson4,
- Philip Raskin5,
- Yefim Anbinder6,
- Andrew P. Levy6,
- the DCCT/EDIC Research Group*
- 1Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
- 2Biostatistics Center, George Washington University, Rockville, Maryland
- 3Department of Medicine, Case Western Reserve University, Cleveland, Ohio
- 4Program in Genetics and Genome Biology, Hospital for Sick Children, Toronto, Ontario, Canada
- 5Southwestern Medical Center, Dallas, Texas
- 6Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
- Corresponding author: Trevor J. Orchard, .
Many patients with type 1 diabetes develop renal disease despite moderately good metabolic control, suggesting other risk factors may play a role. Recent evidence suggests that the haptoglobin (HP) 2-2 genotype, which codes for a protein with reduced antioxidant activity, may predict renal function decline in type 1 diabetes. We examined this hypothesis in 1,303 Caucasian participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. HP genotype was determined by polyacrylamide gel electrophoresis. Glomerular filtration rate was estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and albumin excretion based on timed urine samples. Participants were followed up for a mean of 22 years. HP genotype was significantly associated with the development of sustained estimated glomerular filtration rate (GFR) <60 mL/min/1.73 m2 and with end-stage renal disease (ESRD), with HP 2-2 having greater risk than HP 2-1 and 1-1. No association was seen with albuminuria. Although there was no treatment group interaction, the associations were only significant in the conventional treatment group, where events rates were much higher. We conclude that the HP genotype is significantly associated with the development of reduced GFR and ESRD in the DCCT/EDIC study.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0256/-/DC1.
* A complete list of participants in the DCCT/EDIC Research Group can be found in ref. 1.
- Received February 13, 2013.
- Accepted June 3, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.